《新英格兰医学杂志》发布三期临床研究Ascent-04/Keynote-D19结果:Trodelvy®联合Keytruda®有望成为PD-L1阳性转移性三阴性乳腺癌一线治疗新标准

美股速递
Jan 22

《新英格兰医学杂志》最新刊发的三期临床试验Ascent-04/Keynote-D19研究数据显示,Trodelvy®与Keytruda®联合疗法展现出显著疗效。这一突破性进展为PD-L1阳性转移性三阴性乳腺癌患者的一线治疗提供了新选择。

研究结果证实,联合用药方案在客观缓解率和无进展生存期等关键指标上均优于现有标准疗法。该疗法有望重塑临床实践格局,为晚期三阴性乳腺癌治疗领域注入新动能。

此次发布的数据进一步验证了免疫联合靶向治疗的协同作用机制。随着后续研究推进,这种创新组合或将成为该类患者群体的一线标准治疗方案。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10